Percheron Therapeutics (ASX:PER) expects to deliver topline data from its Duchenne muscular dystrophy (DMD) trial using avicursen from December 16.
DMD is an inherited condition were patients’ muscles degrade overtime, ultimately limiting mobility and risking heart conditions. It is often diagnosed in childhood; there is no cure, though steroids can delay onset.
Technically an inflammatory condition, Percheron has before reported early-stage trial success treating DMD with avicursen, a drug which goes after the way white blood cells behave in the body.
But full-on data is set for release in mid-December, all cards in order, with the company preparing shareholders on Monday.
“All 48 patients enrolled in the trial have now completed their week 25 visit, which is the visit at which the primary endpoint of the study is assessed,” Percheron wrote.
“Barring unforeseen operational delays, the company expects to be in a position to disclose initial topline data, representing the first six months on study for all patients, during the week beginning December 16, 2024.”
Percheron CEO Dr. James Garner was more elaborative with what the milestone means for shareholders.
“This readout will provide the first indication of avicursen’s activity in Duchenne and will help us to better chart its path forward toward registration and commercialisation. This is only the first of three major readouts from the study, and we will learn much more as we progress through CY2025,” Garner said.
“The team has worked hard to generate results as quickly as possible.”
Whether or not you take that as last comment a good thing or a bad thing likely depends on the type of investor you are.
PER last traded at 7.4cps.
Join the discussion: See what HotCopper users are saying about Percheron and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.